Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 1069743, 10 pages
Review Article

Role of Myeloperoxidase in Patients with Chronic Kidney Disease

1Institute of Biochemistry, Medical Faculty Pristina, Kosovska Mitrovica 38220, Serbia
2Institute of Pharmacology, Medical Faculty Pristina, Kosovska Mitrovica 38220, Serbia
3Institute of Pathophysiology, Medical Faculty Pristina, Kosovska Mitrovica 38220, Serbia

Received 11 February 2016; Accepted 14 March 2016

Academic Editor: Alexandra Scholze

Copyright © 2016 Bojana Kisic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Chronic kidney disease (CKD) is a worldwide public health problem. Patients with CKD have a number of disorders in the organism, and the presence of oxidative stress and systemic inflammation in these patients is the subject of numerous studies. Chronic inflammation joined with oxidative stress contributes to the development of numerous complications: accelerated atherosclerosis process and cardiovascular disease, emergence of Type 2 diabetes mellitus, development of malnutrition, anaemia, hyperparathyroidism, and so forth, affecting the prognosis and quality of life of patients with CKD. In this review we presented the potential role of the myeloperoxidase enzyme in the production of reactive/chlorinating intermediates and their role in oxidative damage to biomolecules in the body of patients with chronic kidney disease and end-stage renal disease. In addition, we discussed the role of modified lipoprotein particles under the influence of prooxidant MPO intermediates in the development of endothelial changes and cardiovascular complications in renal failure.